Comparative Efficacy of Trimetazidine and Ranolazine in Patients with Angina

Abstract

Objective: To determine the relative efficacy of two newly available metabolically active drugs Trimetazidine and Ranolazine in a subset of patients whose angina symptoms were not ameliorated with optimum dose of conventional anti-anginal medications (B-Blockers, Calcium Channel Blockers and Nitrates), as further increment in their dosage was detrimental for the rate pressure product.

Study Design: Prospective / Descriptive / cross sectional study

Place and Duration of Study: This study was conducted at the Cardiology Department, DHQ Teaching Hospital Dera Ghazi Khan from November 2016 to December 2016.

Materials and Methods: A total of 106 patients with symptomatic angina from Dera Ghazi Khan urban area were divided into two equal groups each consisting of 53 patients. In group 1 Trimetazidine and in group II Ranolazine was added in addition to their routine optimum treatment. They were evaluated after six weeks through a questionnaire for angina symptoms.

Results: The relief of anginal symptoms was 39.6% in group 1 (Trimetazidine group) while it was 67.9% in group II (Ranolazine group).

Conclusion: The Ranolazine is more effective in controlling the angina symptoms as compared to Trimetazidine as early as six weeks.